Skip to content
10-Q

Quarterly Report

GAIN THERAPEUTICS, INC GANX

0001104659-26-058649

← back to feed
Filed
May 11, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 42.65M sh
Shares Diluted Q1 2026 · Mar 31, 2026 42.23M sh
Shares Diluted Q1 2026 · Mar 31, 2025 28.69M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$4.73M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$3.82M
Long Term Debt Q1 2026 · Mar 31, 2026 $273.27K
Long Term Debt Q1 2026 · Dec 31, 2025 $300.08K
Short Term Debt Q1 2026 · Mar 31, 2026 $100.28K
Short Term Debt Q1 2026 · Dec 31, 2025 $100.87K
Cash And Equivalents Q1 2026 · Mar 31, 2026 $16.54M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $20.84M
Stockholders Equity Q1 2026 · Mar 31, 2026 $14.01M
Stockholders Equity Q1 2026 · Dec 31, 2025 $18.56M
Stockholders Equity Q1 2026 · Mar 31, 2025 $5.78M
Stockholders Equity Q1 2026 · Dec 31, 2024 $7.34M
Current Liabilities Q1 2026 · Mar 31, 2026 $3.89M
Current Liabilities Q1 2026 · Dec 31, 2025 $3.35M
Total Liabilities Q1 2026 · Mar 31, 2026 $4.73M
Total Liabilities Q1 2026 · Dec 31, 2025 $4.25M
Current Assets Q1 2026 · Mar 31, 2026 $18.22M
Current Assets Q1 2026 · Dec 31, 2025 $22.24M
Total Assets Q1 2026 · Mar 31, 2026 $18.74M
Total Assets Q1 2026 · Dec 31, 2025 $22.82M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.13
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.16
Eps Basic Q1 2026 · Mar 31, 2026 −$0.13
Eps Basic Q1 2026 · Mar 31, 2025 −$0.16
Sga Expense Q1 2026 · Mar 31, 2026 $2.59M
Sga Expense Q1 2026 · Mar 31, 2025 $2.11M
Rd Expense Q1 2026 · Mar 31, 2026 $2.76M
Rd Expense Q1 2026 · Mar 31, 2025 $2.26M
Net Income Q1 2026 · Mar 31, 2026 −$5.61M
Net Income Q1 2026 · Mar 31, 2025 −$4.53M
Operating Income Q1 2026 · Mar 31, 2026 −$5.35M
Operating Income Q1 2026 · Mar 31, 2025 −$4.37M